HCPCS code J3265: Torsemide injection billing guide

Key takeaways

HCPCS code J3265 is the Level II J-code for “Injection, torsemide, 10 mg/ml” under Medicare Part B.

One billing unit equals 10 mg/ml administered, so a 20 mg dose bills as 2 units.

Torsemide injection is supplied in single-dose vials only, so every claim carries modifier JZ or JW.

The NDC goes in the shaded portion of field 24A with qualifier N4, never in field 24D.

Practice management software like Pabau keeps the drug code, the units and the NDC on one billing record.

HCPCS code J3265 describes “Injection, torsemide, 10 mg/ml.” It is a Level II HCPCS J-code maintained by the Centers for Medicare and Medicaid Services (CMS). Physicians, outpatient facilities, and hospital-based departments use it to report torsemide given by injection.

One billing unit covers 10 mg/ml administered. Three entries decide whether the claim pays first time: the unit count, the waste modifier, and the NDC of the package that was opened.

Torsemide: Clinical background and injection indications

Torsemide is a loop diuretic that inhibits sodium-potassium-chloride cotransport in the ascending loop of Henle, promoting urinary excretion of fluid. According to FDA drug labeling, torsemide is approved for edema associated with congestive heart failure (CHF), chronic renal failure, and hepatic cirrhosis. It is also approved for hypertension.

The injectable form is used when oral administration is not feasible. It turns up mostly in inpatient and outpatient infusion settings where rapid diuresis is required, usually heart failure management or an acute fluid overload protocol.

• Congestive heart failure (CHF): Acute decompensation with pulmonary or peripheral edema
• Chronic renal failure: Volume overload unresponsive to oral diuretics
• Hepatic cirrhosis: Ascites and peripheral edema management
• Hypertension: Adjunct treatment when parenteral route is necessary

J3265 billing guidelines: Units, modifiers, and place of service

A J3265 claim turns on three entries: the unit count, the applicable modifiers, and the place of service (POS) code. Each one affects reimbursement separately. An error in any of them can trigger a denial or an audit flag.

Units of service

The billing unit for J3265 is per 10 mg/ml administered. If a physician administers 20 mg, bill 2 units. If 30 mg is administered, bill 3 units. Bill only what was actually administered, not what was drawn or wasted from the vial.

JW and JZ waste modifiers

CMS implemented mandatory drug waste modifier reporting for single-dose vials. Two modifiers apply to J3265 claims depending on the circumstances:

• Modifier JZ: Use when there is no discarded drug from the vial (i.e., the full vial was administered). CMS made it mandatory from July 1, 2023 under Change Request 13056 (Transmittal 12067). It states that zero waste occurred, so no separate waste line is filed.
• Modifier JW: Use when a portion of a single-dose vial was discarded. Report the administered portion under J3265 with units reflecting what was given. Report the wasted amount on a second line with modifier JW.

The JW/JZ modifier requirement applies to single-dose vials. Every torsemide injection product on the market is single-dose, so one of the two modifiers belongs on every J3265 claim. Submitting the code without either one may draw a denial from your Medicare Administrative Contractor (MAC).

Place of service codes

Non-facility rates are generally higher because the practice bears the overhead cost of drug administration. Facility rates apply when the hospital or ASC is billing for the facility component separately. Confirm the correct POS with your MAC before submitting, since POS mismatches are among the most common causes of J-code denials.

NDC reporting requirements for J3265

Medicare Part B requires a National Drug Code (NDC) on every claim for a physician-administered drug, including claims submitted under HCPCS code J3265. This requirement is governed by CMS transmittals on outpatient drug claim reporting and applies to all MAC jurisdictions.

The NDC belongs in the shaded portion of field 24A on the CMS-1500, or the equivalent loop on an 837P electronic claim. Field 24D carries the HCPCS code and its modifiers, so the NDC never goes there. Capture the number at the point of administration rather than at billing time, because the package opened is the one that must be reported.

NDC format requirements

• Format: 11-digit number in the format NNNNN-NNNN-NN (no dashes on electronic claims, dashes for paper CMS-1500)
• Qualifier: N4 must precede the NDC on electronic claims (e.g., N412345678901)
• Unit of measure: report the NDC unit count and qualifier (UN = units, ML = milliliters, GR = grams, F2 = international units)
• Source: the FDA drug labeling database lists current NDC codes for torsemide injection products; verify the NDC matches the specific lot and package dispensed

Claims submitted without a valid NDC, or with an NDC in the wrong format, are rejected at the clearinghouse before they reach the MAC. A format check before the claim leaves the practice removes most of those rejections.

The four entries below sit on the same service line, and each carries a different part of the torsemide claim.

Nothing on that line is optional. A missing modifier, a stale NDC, or a unit count taken from the vial size will each stop the claim.

J3265 Medicare reimbursement and fee schedule

Medicare reimburses J3265 based on the Average Sales Price (ASP) methodology. CMS publishes ASP-based payment rates quarterly in the Medicare Part B Drug and Biological Allowances file. Rates change each January, April, July, and October, so any specific dollar figure can be outdated within 90 days.

To look up the current rate, use the CMS Physician Fee Schedule search tool and filter by HCPCS code J3265. The ASP payment limit is typically set at ASP plus 6% for most Part B drugs, though sequestration adjustments apply. MAC-specific rates may differ slightly from the national rate depending on regional fee schedule adjustments.

ICD-10 diagnosis codes commonly used with J3265

Torsemide injection must be supported by a medically necessary diagnosis. Medicare MACs require that at least one ICD-10-CM code on the claim demonstrates clinical justification for the drug. The following codes are most commonly paired with J3265, based on approved torsemide clinical indications and MAC local coverage determinations.

Use the most specific ICD-10-CM code available. “Heart failure, unspecified” (I50.9) is billable but may trigger additional documentation requests. Check whether the chart documents systolic or diastolic heart failure, and the acuity level. Report the matching specific code to reduce medical necessity denials. Specificity is also the cheapest defense against the denial codes that follow a weak medical necessity link.

Documentation requirements

A J3265 claim is only as good as the record behind it. On review, a MAC compares the units billed against what the chart says was given. The medication administration record therefore has to state the dose in milligrams.

• Order and signature: A dated, signed order for torsemide injection stating the dose and the route
• Dose administered: The milligrams given, the concentration, and the volume drawn from the vial
• Date and time: The administration time, plus infusion start and stop times when an administration code is billed
• Product identifiers: The NDC of the package opened, the vial size, and the lot number
• Waste: The amount discarded and the reason, recorded whenever modifier JW is reported
• Medical necessity: The diagnosis supporting diuresis, documented to the specificity of the ICD-10-CM code on the claim
• Supervision: Who administered the drug, and the supervising provider where the service is billed incident-to

Two records have to agree before submission: the administration note and the claim line. Where they disagree on milligrams, the claim is wrong even when the arithmetic on the claim itself is right.

Retain the documentation for as long as your MAC’s record retention policy requires. Payers ask for it during post-payment review, and a missing waste note turns an otherwise clean claim into a repayment.

2026 HCPCS update status for J3265

J3265 was referenced in January 2026 HCPCS code update notices published by CGS Medicare (MAC Jurisdiction B and J) and Noridian Medicare. Based on available information from those MAC publications, J3265 remains an active, continuing code with no descriptor change or retirement for the 2026 code year. Verify the current status against the CMS HCPCS Level II official code files. Those files are the authoritative source for status, effective dates, and descriptor language.

The January 2026 HCPCS update cycle added new drug injection codes and revised descriptors for several existing J-codes. Practices billing J-codes adjacent to J3265, such as the unclassified drug code J3490, should confirm those are still valid before submitting 2026 claims. Use the AAPC HCPCS code lookup to cross-reference descriptor language and effective dates quickly.

Payer coverage and prior authorization for J3265

Medicare Part B covers J3265 when torsemide injection is medically necessary and administered by or under the direct supervision of a qualified provider. Coverage is subject to MAC local coverage determinations (LCDs), which vary by jurisdiction. Check your specific MAC’s coverage articles for J3265 to confirm whether a separate LCD governs loop diuretic injections in your region.

Medicaid coverage for J3265 varies by state. Most state Medicaid programs follow Medicare Part B payment methodology for physician-administered drugs, but prior authorization requirements differ. Contact the state Medicaid program directly or check the payer portal for J3265-specific PA requirements before administering.

Commercial payers do not uniformly follow Medicare’s J-code structure. Some commercial plans require a prior authorization for injectable loop diuretics, while others process the claim using their own drug fee schedule. Practices billing commercial payers for torsemide injection should verify benefit coverage and authorization requirements before treatment.

Related HCPCS codes to know

Coders working with J3265 should know the codes that sit next to it. Choosing the wrong one is how upcoding errors start, and the right choice depends on which drug was actually administered.

J3490 is the unclassified drug fallback, and it should never be used when a specific code exists for the drug administered. Billing it for torsemide is an incorrect code selection and can draw audit attention.

Keeping a drug-to-J-code crosswalk for every physician-administered drug on formulary is what stops that substitution happening under time pressure.

How Pabau supports J3265 billing workflows

Injectable drug billing requires tight coordination between the point of administration and claim submission. The NDC must be captured at the time the vial is used. The unit count must match what was administered, and the modifier must reflect the waste disposition. These steps typically happen across different staff members and systems, which is where errors creep in.

Pabau’s claims management software provides structured billing fields that support J-code claim preparation, including drug code entry, unit calculation, and modifier selection. Practices with a steady volume of injectable drug claims benefit from having those fields inside the billing workflow. The alternative is manual lookups and paper crosswalks.

Pabau also holds scheduling, clinical documentation, and claim preparation in one platform. The administration note and the claim line draw on the same record, which removes the handoff where injectable drug details usually get lost.

Bill injectable drugs without the rework

Pabau’s claims management software keeps the drug code, the unit count and the NDC on one record. J3265 claims leave the practice complete, so fewer of them come back.

Book a demo

Conclusion

Torsemide injection is a low-dollar drug with a high-friction claim. What decides the outcome is whether the units, the waste modifier, and the NDC leave the practice together on one line.

Capture those three while the vial is still in hand and the rest of the claim follows. Rebuild them at billing time and you are guessing at which package was opened, which is where the resubmission cycle starts.

Pabau’s claims management tools standardize J-code billing so the data is recorded at the point of administration. To see how that works on injectable drug claims, book a demo.

Continue your research

Need help building a clean claim checklist for injectable drugs? Clean claim submission guide covers the documentation fields that prevent first-submission denials for J-code drug claims.

Want to understand how denial patterns affect J-code revenue? Denial management in healthcare explains how to track, categorize, and reduce claim denials across drug injection codes.

Need the NDC captured before the claim is built? Superbill documentation shows which drug fields to record at the point of care.

Frequently asked questions